Ann: Investor webinar and Q&A to be held Feb 23rd, page-15

As holders, no one mentioned this??? I'm sure RSH sold wheezo with an option of 12 months subscription fee for only 11 months so these revenue could be accrued for this year but that was from their own website and not through Cipla's distributors and clearly RSH didn't get the 7K units upfront from Cipla for the device or this would be $700K which was what I said they are just distributors and @lucasq wanted to argue with me.

Customers will be paying for wheezo if they see the product as useful (it's only $10 a month in Australia lol) and this will be the same in the US even if CPT is involved, the doctors will recommend wheezo and the consumer decide not to continue to use it anymore a few months like what seems to be happening here. RSH's revenue are from the monthly subscription fee, not the wheezo device as this would be minimal with the manufacturing cost associated with the device.